ArticleProbiotics and antimicrobial proteins2016
Biochemical Properties and Mechanism of Action of Enterocin LD3 Purified from Enterococcus hirae LD3.
Article in Probiotics and antimicrobial proteins, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Safety Assessment of Enterocin LD3 Purified from a Food-Grade Enterococcus hirae LD3.Probiotics and antimicrobial proteins · 2026Article
- The Enterococcus secretome inhibits the growth of vancomycin-resistant Enterococcus faecalis V853 with their antiproliferative properties and nanoencapsulation effects.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Enterocin LD3 from Enterococcus hirae LD3 Inhibits the Growth of Salmonella enterica subsp. enterica serovar Typhimurium ATCC 13311 in Fruit Juice.Probiotics and antimicrobial proteins · 2024Article
- Multi-Omics Approach in Amelioration of Food Products.Frontiers in microbiology · 2022Review
- Bacteriocins: Properties and potential use as antimicrobials.Journal of clinical laboratory analysis · 2022Review
- Can Probiotics Emerge as Effective Therapeutic Agents in Apical Periodontitis? A Review.Probiotics and antimicrobial proteins · 2021Review
- Application of bacteriocins in food preservation and infectious disease treatment for humans and livestock: a review.RSC advances · 2020Review
- Novel enterocin E20c purified from Enterococcus hirae 20c synergised with ß-lactams and ciprofloxacin against Salmonella enterica.Microbial cell factories · 2020Article
- Probiotics at War Against Viruses: What Is Missing From the Picture?Frontiers in microbiology · 2020Review
- Comparative Analysis of Inhibition-Based and Indicator-Independent Colorimetric Assay for Screening of Bacteriocin-Producing Lactic Acid Bacteria.Probiotics and antimicrobial proteins · 2019Article
- Physiological and molecular insights of bacteriocin production by Enterococcus hirae ST57ACC from Brazilian artisanal cheese.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2019Article
- Anti-staphylococcal activity of bacteriocins of food isolates3 Biotech · 2019Article
- Antimicrobial Activity of a Bacteriocin Produced byKorean journal for food science of animal resources · 2018Article
- A Novel High-Molecular-Mass Bacteriocin Produced by Enterococcus faecium: Biochemical Features and Mode of Action.Probiotics and antimicrobial proteins · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterocin LD3 was purified using activity-guided multistep chromatography techniques such as cation-exchange and gel-filtration chromatography. The preparation's purity was tested using reverse-phase ultra-performance liquid chromatography. The specific activity was tested to be 187.5 AU µg(-1) with 13-fold purification. Purified enterocin LD3 was heat stable up to 121 °C (at 15 psi pressure) and pH 2-6. The activity was lost in the presence of papain, reduced by proteinase K, pepsin and trypsin, but was unaffected by amylase and lipase, suggesting proteinaceous nature of the compound and no role of carbohydrate and lipid moieties in the activity. MALDI-TOF/MS analysis of purified enterocin LD3 resolved m/z 4114.6, and N-terminal amino acid sequence was found to be H2NQGGQANQ-COOH suggesting a new bacteriocin. Dissipation of membrane potential, loss of internal ATP and bactericidal effect were recorded when indicator strain Micrococcus luteus was treated with enterocin LD3. It inhibited Gram-positive and Gram-negative bacteria including human pathogens such as Staphylococcus aureus, Pseudomonas fluorescens, Pseudomonas aeruginosa, Salmonella typhi, Shigella flexneri, Listeria monocytogenes, Escherichia coli O157:H7, E. coli (urogenic, a clinical isolate) and Vibrio sp. These properties of purified enterocin LD3 suggest its applications as a food biopreservative and as an alternative to clinical antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.